Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma

Prior to 2011, the 1-year survival rates for patients suffering from advanced or metastatic melanoma was as low as 33%, with a median overall survival of about 9 months. Several chemotherapeutic regimens have been applied, either as monochemotherapy or as polychemotherapy, overall not resulting in a...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: Banzi, Maria, De Blasio, Simona, Lallas, Aimilios, Longo, Caterina, Moscarella, Elvira, Alfano, Roberto, Argenziano, Giuseppe
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2016
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4866744/
https://ncbi.nlm.nih.gov/pubmed/27226731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S75104
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items